Adenocarcinoma endometrial

Apoptosis of cultured hmnan endometrial adenocarcinoma cells and inhibition of cell proliferation (Miyoshi et al.,... 

FAN H, MORIOKA T, iTO E (2000) Induction of apoptosis and growth inhibition of cultured human endometrial adenocarcinoma cells (Sawano) by an anti-mmor lipoproteinfraction of rice bran. Gynacol, Oncol, 76(2) 170-75. 

KodaM,Jarzabek K, HaczynskiJ, Knapp P, SulkowskiS, Wolczynski S (2004) Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line. Oncol Rep 12(3) 517-521... 

Progesterone administration induces remissions in approximately one-third of patients with metastatic endometrial cancer. The mean duration of response is 27 months. Almost 60% of endometrial adenocarcinomas contain progesterone receptors. Preliminary data show a correlation between progesterone receptor status and response rates in this disease. The mechanism of the effect of progesterone on endometrial cancer is not known. 

Apoptosis induction. Lipoprotein fraction of the bran, in cell culture at a concentration of 100 pg/mL, was active vs human endometrial adenocarcinoma cells " . 

Keller C, Nanda R, Shannon RL, Amit A, Kaplan AL. Concurrent primaries of vaginal clear cell adenocarcinoma and endometrial adenocarcinoma in a 39-year old woman with in utero diethylstilbestrol exposure. Int J Gynecol Cancer 2001 ll(3) 247-50. 

Debus G, Schuhmacher I. Endometrial adenocarcinoma arising during estrogenic treatment 17 years after total abdominal hysterectomy and bilateral salpingo-... 

Ewies AAA, Olah KSJ. Endometrial adenocarcinoma treated by hysterectomy and bilateral salpingo-oophorectomy at age 22-the dilemma of long-term HRT. J Obstet Gynaecol 2000 20 639 10. 

The present data clearly demonstrate that the novel nonsteroidal antiestrogen EM-800 and its active metabolite EM-652 exert pure antagonistic effects while being the most potent of the compounds tested on E2-induced alkaline phosphatase activity in human Ishikawa endometrial adenocarcinoma cells. Hydroxytamoxifen and hydroxy toremifene, in contrast to EM-652, exert a stimulatory effect on this estrogen-sensitive parameter, an effect that can be competitively blocked by simultaneous exposure to the antiestrogen EM-652, EM-652-HC1, or EM-800, thus supporting the suggestion that the stimulatory effect of these... 

Mesonephric duct remnants may be found in the deep wall of cervix specimens. Sometimes, hyperplasia may be pronounced and raise concern for minimal deviation type endocervical adenocarcinoma. Apical expression of CD 10 is common in these remnants, as is expression by the intraluminal secretions. CD 10, however, is not pathognomonic for mesonephric differentiation because some endocervical and endometrial adenocarcinomas may express CDIO. Minimal deviation type endocervical adenocarcinoma, however, lacks CDIO expression. Variable expression of pi6 is reported in mesonephric remnants and may lead to misinterpretation as endocervical adenocarcinoma however, MIBl is not increased. ER, PR, and CEA are generally negative. The immuno-phenotype is similar in mesonephric adenocarcinoma as well. " ... 

Primary endocervical adenocarcinoma is usually positive for pi 6 and CEA and negative for vimentin and ER, while primary endometrial adenocarcinoma is usually the converse. 

Vimentin, an intermediate filament, is expressed in mesenchymal tissues, normal proliferative endometrial epithelial cells, and in the majority of endometrial carcinomas.jj g coexpression of vimentin and low molecular weight cytokeratin can aid in the differential diagnosis of an endocervical versus an endometrial adenocarcinoma. 

Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas Immunohistochemical pi6 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004 28 160-167. 

Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophe-notypic diversity of endometrial adenocarcinomas Implications for differential diagnosis. Mod Pathol. 2006 19 1091-1100. 

Meis JM, Lawrence WD. The immunohistochemical profile of malignant mixed miillerian tumor. Overlap with endometrial adenocarcinoma. Am J Clin Pathol. 1990 94 1-7. 

Alkushi A, Clarke BA, Akbari M, et al. Identification of prog-nostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol. 2007 20 1156-1165. 

Albannai RA, Alkushi A, Gilks CB. Serous and endometrioid components of mixed endometrial adenocarcinoma show similar immunostaining profiles. Mod Pathol. 2009 21 194A. 

Nascimento AF, Hirsch MS, Cviko A, et al. The role of CDIO staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis. Mod Pathol. 2003 16 22-27. 

McKenney JK, Kong CS, Longacre TA. Endometrial adenocarcinoma associated with subtle lymph-vascular space invasion and lymph node metastasis A histologic pattern mimicking intravascular and sinusoidal histiocytes. Int J Gynecol Pathol. 2005 24 73-78. 

Table 2. Relative potency of some phytoestrogens in human endometrial adenocarcinoma cells [9].

Simard J, Sanchez R, et al. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 1997 57 3494-3497. 

Nishida, M., Kasahara, K., Kaneko, M., Iwasaki, H., and Hayashi, K., Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors, Nippon Sanka Fujinka Gakkai Zasshi, 37, 1103, 1985. 

---